Skip to main content
$6.24 +0.18 (+2.97%)
Market Cap
$227.14M
Shares
37.48M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-06-30 FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced the

2026-06-16 FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical AUSTIN, Texas, June 16, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), the global leader in robotic focal therapy, today announced that it has

2026-05-29 EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026 Company Intends to Report and Classify its Legacy

2026-05-21 EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4 th, 2026 AUSTIN, Texas, May 21 th, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic

2026-05-14 EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of

2026-05-13 EDAP | Focal One to Host Investor Day on June 1, 2026

EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at

2026-05-07 EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue

EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year 53% Growth in First Quarter U.S.

2026-04-30 EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer AUSTIN, Texas, April 30, 2026 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced

2026-04-16 EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic

2026-03-25 EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures 69% Full-Year YoY Growth in Focal One System Placements 28% Q4 YoY Growth in

Past events

Source: https://investor.focalone.com/

Key facts CIK 1041934 CUSIP 268311107 13F (30d) 5 filings 5 filers Visit website Investor relations